-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

2848 Poor Prognosis of SRSF2 Gene Mutations in Patients Treated with Venetoclax-Azacitidine (VEN-AZA) for Newly Diagnosed Acute Myeloid Leukemia. a Multicentric Real-Life Study of 117 Patients

Program: Oral and Poster Abstracts
Session: 613. Acute Myeloid Leukemias: Clinical and Epidemiological: Poster II
Hematology Disease Topics & Pathways:
Research, Acute Myeloid Malignancies, AML, adult, Clinical Research, Diseases, real-world evidence, Myeloid Malignancies, Technology and Procedures, Study Population, Human, molecular testing
Sunday, December 10, 2023, 6:00 PM-8:00 PM

Guillaume Berton1*, Bochra Sedaki2*, Erwann Collomb3*, Sami Benachour, MD2*, Michael Loschi, MD, PhD4*, Bilal Mohty, MD5*, Colombe Saillard, MD5*, Yosr Hicheri5*, Camille Rouzaud, MD5*, Valerio Maisano, MD6*, Ferdinand Villetard, MD7*, Evelyne D'Incan Corda, MD7*, Aude Charbonnier, MD, PhD5*, Jerome Rey, MD5*, Marie Anne Hospital7*, Antoine Ittel, PharmD8*, Norman Abbou9*, Raphaelle Fanciullino10*, Bérengère Dadone-Montaudié11*, Norbert Vey, MD12, Geoffroy Venton, MD, PhD13*, Thomas Cluzeau, MD, PhD14, Anne Sophie Alary15* and Sylvain Garciaz12*

1Hematology Department, Institut Paoli-Calmettes, Marseille, AL, France
2Hematology Department, Nice University Hospital, Cote d’Azur University, Nice, France
3Hematology and Cellular Therapy Department, La Conception University Hospital, Marseille, France
4Centre Hospitalier Universitaire de Nice, Nice, France
5Department of Hematology, Institut Paoli-Calmettes, Marseille, France
6Hematology Department, Institut Paoli-Calmettes, Marseille, FRA
7Hematology Department, Institut Paoli-Calmettes, Marseille, France
8Department of Molecular Biology, Institut Paoli-Calmettes, Marseille, France
9CHU Nord, Marseille, France
10Aix Marseille Univ, Marseille, FRA
11Department of Pathology and Molecular Oncology, Molecular Oncology Unit, Nice University Hospital, Nice, France
12Aix-Marseille University, INSERM U1068, CNRS, Institut Paoli-Calmettes, CRCM, Marseille, France
13University Hospital Center of Marseille, Marseille, France
14Nice University Hospital, Nice, Provence Alpes Cote d'Azur, France
15Department of Biopathology, Institut Paoli-Calmettes, Marseille, France


Spliceosomes are complexes composed of small nuclear RNA that remove introns in protein-encoding genes. Spliceosome mutations (SRSF2, SF3B1, U2AF1, ZRSR2), are encountered in 50% of secondary AML cases. Splicing mutations (splice-mut), in particular SRSF2, correlate with inferior outcomes to standard induction therapy. A recent report in a cohort of 119 patients, of whom 33 had splice mutations and 24 were SRSF2 mutated, reported the lack of impact of splice-mut on prognosis of AML patients treated upfront with Hypomethylating agents (HMA) + VEN in clinical trials (Lachowiez, C. A. et al, Blood Adv. 2021).


We aimed to assess the impact of splice-mut in a population of patients with newly diagnosed acute myeloid leukemia (ND-AML), treated with VEN-AZA.


We performed a retrospective multicentric study including patients treated in three French centers in Marseille (Institut Paoli-Calmettes, CHU La Conception) and Nice (Hôpital L’Archet). Inclusion criterias were ND AML adult patients treated with VEN (7 to 28 days per cycle) and AZA at conventional doses. Next Generation Sequencing (NGS) was performed at diagnosis and was available for all patients. Data were collected from patients’ electronic medical records. Statistical analyses were performed using GraphPad Prism v9.5.1


We included 117 ND-AML patients (median age = 75 yo; range, 32-89) treated with VEN-AZA between October 2019 and March 2023. The five most frequently mutated genes in the whole cohort were TET2, ASXL1, TP53 and RUNX1in thirty-seven (32%), 36 (31%), 32 (27%) and 31 (26%) patients, respectively. Thirty-four patients (29%) had a mutation in at least one of the spliceosome genes (=Splice-mut), including 20 (17%), 11 (9%), 4 (3%) and 1 (1%) mutations in SRSF2, U2AF1, SF3B1 and ZRSR2, respectively (Fig.1). Median variant allele frequency (VAF) was 42%, 43% and 26% for SRFS2, U2AF1 and SF3B1, respectively. Secondary AML was found in 18 (53%) of the splice-mut AML and 21 (25.3%) of the splice-wt AML groups of patients. Prior HMA was given in seven (20.6%) patients in the splice-mut versus 6 (7.2%) in the splice-wt cohort. Complex cytogenetics was identified in 7 (20.6%) patients in the splice-mut cohort and 28 (33.7%) in the splice-wt cohort. We found a TP53 mutation in 17.6% and 31.3% of splice-mut and wt cohorts, respectively. Best overall response rate (= CR, CRi and MLFS) was 72.6%; with CR, CRi and MLFS observed in 63 (54%), 16 (14%) and 6 (5%) patients, respectively. We did not find any difference in response rate between the splice-mut (=73.5%) and splice-wt (72.3%) AML. Prior treatment with hypomethylating agents and TET2 mutation were the only factors significantly associated with lower response rates (42% vs 82%, p=0.004, and 64% vs 85%, p=0.025, respectively), while IDH2 mutation was predictive of a better response (100%vs 75%, p=0.037, OR: 9.9 [CI 95% 0.57-173]). Median overall survival (OS) and leukemia-free survival (LFS) for the whole cohort was 10.8 and 7.1 months, respectively. In multivariate analysis taking into accountTP53 and/or del17p, NRASmut and/or FLT3-ITD, IDH2mut, complex karyotype, and SRSF2, the only factors predicting OS and LFS were mutations in TP53 and SRSF2 genes. Patients mutated for SRSF2 had a 4.8 months OS and a 5 months LFS compared to 11.3 and 8 months, respectively (p=0.034 and p=0.037), comparable with TP53mut AML patients (Fig.2).


SRSF2mut seems to be predictive of a worse survival in ND AML treated with VEN-AZA. This finding warrants further exploration in larger cohorts.

Disclosures: Loschi: AstraZeneca: Honoraria; BMS: Honoraria; Gilead: Honoraria; GSK: Honoraria; Jazz: Honoraria; Kartos: Honoraria; Medac: Honoraria; MSD: Honoraria; Novartis: Honoraria; Pfizer: Honoraria; Sanofi: Honoraria; Sobi: Honoraria; Telios: Honoraria; Alexion: Honoraria. Charbonnier: Pfizer, Novartis, Incyte Biosciences: Honoraria. Venton: Novartis, Abbvie, Jazz, BMS, Janssen, GSK, Astrazeneca, Gilead: Consultancy. Cluzeau: Incyte: Speakers Bureau; Servier: Consultancy, Speakers Bureau; Keros: Speakers Bureau; Syros: Speakers Bureau; Jazz Pharma: Consultancy, Speakers Bureau; Abbvie: Consultancy, Speakers Bureau; Novartis: Consultancy, Speakers Bureau; BMS: Consultancy, Speakers Bureau.

*signifies non-member of ASH